Clinical Trials /

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

NCT02361112

Description:

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer: To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Completed

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
  • Official Title: A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

Clinical Trial IDs

  • ORG STUDY ID: BLTN-Ic
  • NCT ID: NCT02361112

Conditions

  • Metastatic Breast Cancer

Interventions

DrugSynonymsArms
pyrotinib combined with capecitabinepyrotinib combined with capecitabine

Purpose

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib in combination with capecitabine in patients with HER2 positive metastatic breast cancer: To evaluate the safety and tolerability of pyrotinib, and the maximum tolerated dose (MTD) To determine the dose-limiting toxicity (DLT) To determine the pharmacokinetic profile of Pyrotinib To assess preliminary antitumor activity To determine preliminary regimen dose for phase II study

Trial Arms

NameTypeDescriptionInterventions
pyrotinib combined with capecitabineExperimental
  • pyrotinib combined with capecitabine

Eligibility Criteria

        Inclusion Criteria:

          -  Aged ≥18 and ≤70 years.

          -  ECOG performance status of 0 to 1.

          -  Life expectancy of more than 12 weeks.

          -  At least one measurable lesion exists.(RECIST 1.1)

          -  Histologically or cytologic confirmed HER2 positive metastatic breast cancer which
             failed prior therapies.

          -  No previous treatment of capecitabin during the past 1 year.

          -  Required laboratory values including following parameters:

        ANC: ≥ 1.5 x 109/L Platelet count: ≥ 100 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤
        1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate:
        ≥ 50 mL/min LVEF: ≥ 50% QTcF: < 470 ms

          -  Signed informed consent.

        Exclusion Criteria:

          -  Subjects with third space fluid that can not be controled by drainage or other
             methods.

          -  Steroid treatment for more than 50 days, or in need of long-term use of steroids.

          -  Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal
             absorption.

          -  Less than 4 weeks from the last radiotherapy,chemotherapy,surgery,hermone
             treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin
             chemotherapy.

          -  Subjects with no efficacy during the previous treatment of capecitabine.

          -  Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.

          -  Subjects who can not interrupt the using of the drugs that may cause QT prolongation
             during study.

          -  Subjects with intracranial lesions.

          -  Subjects with bone or skin as the only target lesion

          -  Treated or treating with HER2 tyrosine kinase inhibitors (TKIs) before study entry.

          -  Receiving any other antitumor therapy.

          -  Less than 4 weeks from the last clinical trial.

          -  Known history of hypersensitivity to pyrotinib、capecitabine or any of its components
             or metabolites.

          -  Ongoing infection (determined by investigator).

          -  History of immunodeficiency, including HIV-positive, suffering from other acquired,
             congenital immunodeficiency disease, or history of organ transplantation.

          -  Subjects had any heart disease, including: (1) angina; (2) requiring medication or
             clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5)
             Any heart diseases judged by investigator as unsuitable to participate in the trial.

          -  Female patients who are pregnancy, lactation or women who are of childbearing
             potential tested positive in baseline pregnancy test.

          -  Female patients of childbearing age that are reluctant to take effective contraceptive
             measures throughout the trial period.

          -  Evidence of significant medical illness that in the investigator's judgment will
             substantially increase the risk associated with the subject's participation in and
             completion of the study. Examples include, but are not limited to,hypertension, severe
             diabetes, or thyroid disease.

          -  Alcoholism, smoking (daily ≥ 5 roots) and other bad habits.

          -  Known history of neurological or psychiatric disease, including epilepsy or dementia.
      
Maximum Eligible Age:70 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:The maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one subject out of three experiences has a dose-limiting toxicity (DLT) upon completing one treatment cycle.
Time Frame:21 days
Safety Issue:
Description:DLT was difined as the cetain AEs which were observed during the first cycle (D1-D21)of treatment.

Secondary Outcome Measures

Measure:Cmax, Tmax, T1/2, AUCss and R of pyrotinib and capecitabine in combination
Time Frame:12 months
Safety Issue:
Description:
Measure:the number of participants with adverse event
Time Frame:12 months
Safety Issue:
Description:
Measure:preliminary antitumor activity for the regimen, objective response rate
Time Frame:12 months
Safety Issue:
Description:

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Jiangsu HengRui Medicine Co., Ltd.

Last Updated

June 7, 2016